Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis

Background The aim of the present study was to compare the reported efficacy and safety of glucagon‐like peptide‐l receptor agonist (GLP‐1RA) and insulin glargine (IGlar) for poorly controlled type 2 diabetes. Methods Medline, EMBASE, Cochrane Library, and clinicaltrials.gov were carried out. Refere...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes 2015-05, Vol.7 (3), p.322-328
Main Authors: Liu, Fu-peng, Dong, Jian-jun, Yang, Qing, Xue, Xian-zhong, Ren, Zhong-fa, Gan, Yi-zhang, Liao, Lin
Format: Article
Language:English
Subjects:
Cholesterol
Diabetes
diabetes mellitus
Diabetes Mellitus, Type 2 - drug therapy
Drug therapy
GLP-1 receptor agonist
Glucagon-Like Peptide-1 Receptor - agonists
Humans
hyperlipidemia
Hypoglycemic Agents - therapeutic use
insulin glargine
Insulin Glargine - therapeutic use
关键词：糖尿病，GLP-1受体激动剂，高血脂，甘精胰岛素
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The aim of the present study was to compare the reported efficacy and safety of glucagon‐like peptide‐l receptor agonist (GLP‐1RA) and insulin glargine (IGlar) for poorly controlled type 2 diabetes. Methods Medline, EMBASE, Cochrane Library, and clinicaltrials.gov were carried out. References and cited papers of relevant articles were also checked. Results Seven trials met the inclusion criteria. GLP‐1RA showed equivalent or superior efficacy to IGlar for reducing hemoglobin A1c (HbA1c), with a greater proportion of patients achieving HbAlc
ISSN:1753-0393
1753-0407
DOI:10.1111/1753-0407.12200